Zanubrutinib in RR-MCL @SeattleCCA

Zanubrutinib in RR-MCL @SeattleCCA

obr

4 months
7 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).
Up Next Autoplay